Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
作者信息
Matsubara Nobuaki, Mukai Hirofumi, Hosono Ako, Onomura Mai, Sasaki Masaoki, Yajima Yoko, Hashizume Kensei, Yasuda Masanobu, Uemura Miho, Zurth Christian
机构信息
Division of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan.
Clinical Development, Bayer Yakuhin, Osaka, Japan.
出版信息
Cancer Chemother Pharmacol. 2017 Dec;80(6):1073-1077. doi: 10.1007/s00280-017-3433-3.
Abstract
摘要
相似文献
1
Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.《新一代雄激素受体拮抗剂达洛鲁胺（ODM-201）在日本转移性去势抵抗性前列腺癌患者中的1期研究》勘误
Cancer Chemother Pharmacol. 2017 Dec;80(6):1073-1077. doi: 10.1007/s00280-017-3433-3.
2
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.新一代雄激素受体拮抗剂达洛鲁胺（ODM-201）在日本转移性去势抵抗性前列腺癌患者中的1期研究。
Cancer Chemother Pharmacol. 2017 Dec;80(6):1063-1072. doi: 10.1007/s00280-017-3417-3. Epub 2017 Aug 11.
3
Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.达罗他胺的临床开发：一种用于前列腺癌治疗的新型雄激素受体拮抗剂。
Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24.
4
Darolutamide (ODM-201) for the treatment of prostate cancer.达洛鲁胺（ODM - 201）用于治疗前列腺癌。
Expert Opin Pharmacother. 2017 Jun;18(9):945-952. doi: 10.1080/14656566.2017.1329820. Epub 2017 May 24.
5
Darolutamide For Castration-Resistant Prostate Cancer.达洛鲁胺用于去势抵抗性前列腺癌。
Onco Targets Ther. 2019 Oct 23;12:8769-8777. doi: 10.2147/OTT.S197244. eCollection 2019.
6
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).迈向精准泌尿肿瘤学：利用新型抑制剂达罗他胺（ODM-201）靶向恩杂鲁胺耐药前列腺癌和雄激素受体突变体。
Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26.
7
[Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].达洛鲁胺：一种用于非转移性去势抵抗性前列腺癌的新药
Zhonghua Nan Ke Xue. 2020 Apr;26(4):364-368.
8
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.ODM-204，一种新型 CYP17A1 和雄激素受体双重抑制剂：在去势抵抗性前列腺癌男性中进行的 I 期剂量递增的早期结果。
Eur Urol Focus. 2020 Jan 15;6(1):63-70. doi: 10.1016/j.euf.2018.08.022. Epub 2018 Sep 5.
9
Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.达洛鲁胺作为第二代雄激素受体抑制剂在前列腺癌治疗中的应用
Curr Mol Med. 2021;21(4):332-346. doi: 10.2174/1566524020666200903120344.
10
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.ODM-201 治疗进展性转移性去势抵抗性前列腺癌（ARADES）患者的活性和安全性：一项开放标签 1 期剂量递增和随机 2 期剂量扩展试验。
Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25.
引用本文的文献
1
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study.达罗他胺治疗去势抵抗性前列腺癌患者的功能评估：DaroAcT研究结果
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyae287.
2
Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide.新一代雄激素受体抑制剂-达罗他胺的临床药代动力学和药效学。
Clin Pharmacokinet. 2023 Aug;62(8):1049-1061. doi: 10.1007/s40262-023-01268-w. Epub 2023 Jul 17.
本文引用的文献
1
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.恩杂鲁胺用于未经化疗的转移性去势抵抗性前列腺癌男性患者：3期PREVAIL研究的扩展分析
Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28.
2
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.在化疗初治转移性去势抵抗性前列腺癌患者中的药代动力学、抗肿瘤活性和安全性：一项开放标签的 1 期研究。
Eur Urol. 2016 May;69(5):834-40. doi: 10.1016/j.eururo.2015.09.046. Epub 2015 Oct 17.
3
Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.2009年日本的癌症发病率及发生率：针对日本癌症发病率监测（MCIJ）项目的32个基于人群的癌症登记处的研究。
Jpn J Clin Oncol. 2015 Sep;45(9):884-91. doi: 10.1093/jjco/hyv088. Epub 2015 Jul 3.
4
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.发现新一代雄激素受体抑制剂ODM-201，其针对雄激素信号导向的前列腺癌治疗的耐药机制。
Sci Rep. 2015 Jul 3;5:12007. doi: 10.1038/srep12007.
5
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.醋酸阿比特龙联合泼尼松对比安慰剂联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌患者（COU-AA-302）：一项随机、双盲、安慰剂对照的 3 期研究的最终总生存分析。
Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.
6
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.ODM-201 治疗进展性转移性去势抵抗性前列腺癌（ARADES）患者的活性和安全性：一项开放标签 1 期剂量递增和随机 2 期剂量扩展试验。
Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25.
7
New agents for prostate cancer.用于前列腺癌的新药物。
Ann Oncol. 2014 Sep;25(9):1700-1709. doi: 10.1093/annonc/mdu038. Epub 2014 Mar 20.
8
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.除阿比特龙之外：转移性去势抵抗性前列腺癌的新型激素疗法
Cancer Biol Ther. 2014 Feb;15(2):149-55. doi: 10.4161/cbt.26724. Epub 2013 Nov 1.
9
Castration-resistant prostate cancer: from new pathophysiology to new treatment.去势抵抗性前列腺癌：从新的病理生理学到新的治疗方法。
Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11.
10
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.一项评估单药来那度胺（瑞复美）在复发或难治性外周 T 细胞非霍奇金淋巴瘤患者中的安全性和疗效的 2 期、多中心、单臂、开放标签研究：EXPECT 试验。
Eur J Cancer. 2013 Sep;49(13):2869-76. doi: 10.1016/j.ejca.2013.04.029. Epub 2013 May 31.
Zotero 插件